Sign up
Pharma Capital

Nemaura Medical is developing a 'non-invasive and affordable' glucose monitor

Nemaura Medical Inc's (NASDAQ:NMRD) Chief Business Officer Bashir Timol sat down with Proactive Investors at the LD Micro Conference in New York.

Nemaura is a medical technology company based in the UK, which specializes in the production of specialty medical devices. Its chief product is sugarBEAT, which monitors glucose levels in people with type 1 and type 2 diabetes and can be used to screen pre-diabetic patients as well.


View full NMRD profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.